Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amylyx Pharmaceuticals, Inc. - Common Stock
(NQ:
AMLX
)
1.755
-0.135 (-7.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Amylyx Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations
February 13, 2024
From
Gibbs Law Group
Via
Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, and Amylyx and Encourages Investors to Contact the Firm
February 13, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc. (AMLX) Investors
February 13, 2024
From
Kirby McInerney LLP
Via
Business Wire
AMYLYX PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
February 12, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMLX
February 12, 2024
From
Rosen Law Firm
Via
Business Wire
AMLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Amylyx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
February 12, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
AMLX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Amylyx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
February 12, 2024
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
AMYLYX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Amylyx Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
February 09, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
AMLX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Amylyx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Amylyx Class Action Lawsuit
February 09, 2024
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
February 08, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
3 small-cap biotechs with potential breakthroughs in 2024
February 06, 2024
These small-cap biotech stocks feature large addressable markets combined with positive analyst sentiment and potential breakthroughs in 2024.
Via
MarketBeat
Topics
Bankruptcy
Exposures
Financial
Legal
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Amylyx Stockholders and Encourages Investors to Contact the Firm
January 06, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)
December 22, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS
December 04, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
These biotechs targeting multiple neurodegenerative diseases
December 01, 2023
A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market.
Via
MarketBeat
Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 29, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer
November 28, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND
November 27, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Amylyx Stockholders and Encourages Investors to Contact the Firm
November 15, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Amylyx Pharmaceuticals, Inc. (AMLX)
November 14, 2023
From
Kirby McInerney LLP
Via
Business Wire
Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023
November 02, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals to Present Clinical Trial Design of ORION, a Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy (PSP), at the Neuro2023 PSP and CBD International Research Symposium
October 19, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process
October 13, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial Control
October 10, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France
October 05, 2023
From
Amylyx Pharmaceuticals
Via
Business Wire
RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) Meeting
October 02, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
September 05, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results
August 10, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.